Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:13 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 921 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: SCD Clear all

Conditions: Sickle Cell Disease, Sickle Cell Anemia
Interventions: Chart Review, Survey; Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Sickle Cell Disease
Interventions: Crizanlizumab, Placebo; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 100 Years
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 17
States / cities: Birmingham, Alabama • Orange, California • Washington D.C., District of Columbia + 13 more

Conditions: Chronic Kidney Diseases, Sickle Cell Disease
Interventions: No intervention; Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 5 Years to 29 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Healthy Volunteers Sickle Cell Disease, Thalassemia
Interventions: Etavopivat; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Sickle Cell Disease
Interventions: Plerixafor; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2025
U.S. locations: 2
States / cities: New York, New York

Conditions: Sickle Cell Disease, Pain
Interventions: The Balance Program; Behavioral
Lead sponsor: Children's National Research Institute; Other
Eligibility: 8 Years to 17 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Left Ventricular Systolic Dysfunction, Congestive Heart Failure, Ischemic and Non-ischemic Cardiomyopathy, Sudden Cardiac Death Primary Prevention
Interventions: Not listed
Lead sponsor: Seattle Institute for Cardiac Research; Other
Eligibility: 18 Years to 90 Years
Enrollment: 1,855 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Bellevue, Washington

Conditions: Anemia, Sickle Cell
Interventions: SELFY (Self Management for Youth with SCD); Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Hemoglobin SC Disease, Sickle Cell Anemia
Interventions: Recombinant-methionyl human stem cell factor; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Anemia, Sickle Cell
Interventions: Magnesium Pidolate, Hydroxyurea; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 3 Years to 15 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Sickle Cell Disease, Venous Thrombosis, Sickle Cell Trait, Hypercoagulable State, Venous Thromboembolism
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sickle Cell Disease
Interventions: SelG1, Placebo; Drug
Lead sponsor: Reprixys Pharmaceutical Corporation; Industry
Eligibility: 16 Years to 65 Years
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 49
States / cities: Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 46 more

Conditions: Sickle Cell Disease
Interventions: Anumigilimab, Placebo; Biological · Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 14
States / cities: Little Rock, Arkansas • Orange, California • Hollywood, Florida + 11 more

Conditions: Sickle Cell Disease
Interventions: Prasugrel (clinical formulation), Prasugrel (Orally Disintegrating Tablet [ODT]); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Anemia, Sickle Cell
Interventions: ARU-1801; Genetic
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 18 Years to 45 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Sickle Cell Disease, Vaso-Occlusive Pain Episode in Sickle Cell Disease, Ketamine Infusion, Pain Management, Vaso-Occlusive Crises
Interventions: Sub-dissociative Ketamine Infusion, Normal Saline Placebo Infusion; Drug
Lead sponsor: Mohsen Saidinejad; Other
Eligibility: 5 Years to 20 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Torrance, California

Conditions: Sickle Cell Disease, Thalassemia
Interventions: Video recording, Medication Administration Log, Education; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 5 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Sickle Cell Disease
Interventions: Pain self-management, Education; Behavioral
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 12 Years to 18 Years
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 3
States / cities: Hartford, Connecticut • Atlanta, Georgia • Seattle, Washington

Conditions: Sickle Cell Disease
Interventions: Docosahexaenoic Acid, Placebo; Drug
Lead sponsor: Micelle BioPharma Inc; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 11
States / cities: Birmingham, Alabama • Oakland, California • Gainesville, Florida + 8 more

Conditions: Sickle Cell Disease, Sickle Cell Anemia
Interventions: Hydroxyurea; Drug
Lead sponsor: Lifespan; Other
Eligibility: 6 Months to 21 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 13
States / cities: Phoenix, Arizona • Atlanta, Georgia • Peoria, Illinois + 9 more

Conditions: Muscular Dystrophy, Arrhythmia, Sudden Cardiac Death
Interventions: Screening; Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 448 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2015
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Sickle Cell Disease
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 16 Years and older
Enrollment: 297 participants
Timeline: 2021 – 2022
U.S. locations: 11
States / cities: Birmingham, Alabama • Wilmington, Delaware • St. Petersburg, Florida + 8 more

Conditions: Healthy Volunteers, Sickle Cell Disease, Thalassemia
Interventions: Etavopivat, Moxifloxacin, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Sickle Cell Disease
Interventions: Haploidentical Transplant, Alemtuzumab, Total Body Irradiation, Cyclophosphamide, Sirolimus; Procedure · Drug · Radiation
Lead sponsor: Damiano Rondelli, MD; Other
Eligibility: 16 Years to 60 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Hydroxyurea Exposure Limiting Pregnancy and Follow-Up Lactation

A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

Sickle Cell Uric Acid (SCUA) - Cohort Repository

A Research Study of the Effect of Food on Etavopivat in Healthy Participants

Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells and Evaluation of Globin Gene Transfer in Patients With Sickle Cell Disease

Preliminary Feasibility and Efficacy of Behavioral Intervention to Reduce Pain-Related Disability in Pediatric SCD

SCD-HeFT 10 Year Follow-up

A Self-Management Intervention for Youth With Sickle Cell Disease and Their Families: Phase I

A Phase I/II Trial of Recombinant-Methionyl Human Stem Cell Factor (SCF) in Adult Patients With Sickling Disorders

Use of Hydroxyurea and Magnesium Pidolate for Treatment of Sickle Cell Disease

Venous Thrombosis Biomarkers in Sickle Cell Disease and Sickle Cell Trait

Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises

Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)

A Relative Bioavailability Study of a Prasugrel Orally Disintegrating Tablet

Gene Transfer for Patients With Sickle Cell Disease

Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults

Use of Mobile Technology for Intensive Training in Medication Management

iCanCope With Sickle Cell Pain

Dose-Finding Study of SC411 in Children With Sickle Cell Disease

Hydroxyurea Optimization Through Precision Study

Arrhythmias in Myotonic Muscular Dystrophy

Patient Characteristics and Treatment Patterns From Early Crizanlizumab Use in Real-world Setting: Preliminary Analysis From Select Sickle Cell Centers

A Study on the Effect of Etavopivat on Heart Rhythm in Healthy Participants

SCD-Haplo: Phase II Study of HLA-Haploidentical SCT for Aggressive SCD